<DOC>
	<DOCNO>NCT02449018</DOCNO>
	<brief_summary>To evaluate efficacy , safety tolerability multiple dos QBW251 v placebo administer orally , airway function , lung volume , quality life patient chronic obstructive pulmonary disease ( COPD )</brief_summary>
	<brief_title>A Safety , Tolerability Efficacy Study With QBW251 COPD Patients With QBW251</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Must diagnosis GOLD IIIII chronic obstructive pulmonary disease ( COPD ) ; Must clinical diagnosis chronic bronchitis ; Must either current smoker ( smoke â‰¤ 1 pack per day average last 3 month least 10 pack year smoke history ) OR exsmoker least 10 pack year smoke history ; Must receive chronic , daily , systemic steroid ; Must severe emphysema ( determined HRCT ) ; Must COPD exacerbation respiratory tract infection require antibiotic oral steroid hospitalization within 6 week screen ; Must pregnant nurse woman child bear potential ; Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>COPD ,</keyword>
	<keyword>chronic bronchitis ,</keyword>
	<keyword>inflammation ,</keyword>
	<keyword>airway ,</keyword>
	<keyword>LCI ,</keyword>
	<keyword>pulmonary function test ,</keyword>
	<keyword>lung function ,</keyword>
	<keyword>control clinical trial ,</keyword>
	<keyword>randomize ,</keyword>
	<keyword>airflow ,</keyword>
	<keyword>smoker</keyword>
</DOC>